Across TCGA pan-cancer cohorts, MRPL38 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MRPL38 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MRPL38 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MRPL38 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where MRPL38 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.539	0.286	.002	36	view →
LUAD	DFS	Quartile	All	0.475	1.000	.004	11	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.765	.014	6	view →
HNSC	DFS	Median	All	0.767	0.317	.045	6	view →
CCRCC	DFS	Quartile	All	0.847	0.605	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: MRPL38 tumor-vs-normal RNA expression · all MRPL38 data types